Cabozantinib and Dostarlimab in Recurrent Gynecologic Carcinosarcoma
University of Alabama at Birmingham
University of Alabama at Birmingham
National Cancer Institute (NCI)
Karyopharm Therapeutics Inc
AstraZeneca
Institut du Cancer de Montpellier - Val d'Aurelle
AstraZeneca
Genmab
Northwestern University
Northwestern University
M.D. Anderson Cancer Center
Atavistik Bio, Inc
Centre Oscar Lambret
Abramson Cancer Center at Penn Medicine
Pfizer
M.D. Anderson Cancer Center
Dana-Farber Cancer Institute
University of Miami
Queensland Centre for Gynaecological Cancer
DL Analytics
Dana-Farber Cancer Institute
University of Alabama at Birmingham
Rutgers, The State University of New Jersey
University of Kentucky
National Institutes of Health Clinical Center (CC)
Seagen Inc.
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Yuri Semenyuk Rivne Regional Clinical Hospital
Washington University School of Medicine
City of Hope Medical Center
University Health Network, Toronto
Icahn School of Medicine at Mount Sinai
Shasqi, Inc.
Dana-Farber Cancer Institute
Stanford University
University of Virginia
University of California, San Diego
Bakirkoy Dr. Sadi Konuk Research and Training Hospital
Emory University
Washington University School of Medicine
Northwell Health
Sensei Biotherapeutics, Inc.
Jonsson Comprehensive Cancer Center
Incyte Corporation
Leap Therapeutics, Inc.
University of Alabama at Birmingham
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Abramson Cancer Center at Penn Medicine
M.D. Anderson Cancer Center
Northwestern University
Precision Biologics, Inc